Ge Long Hui·2026-01-14 11:10Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical, has recently had its drug registration application for injectable erythromycin lactobionate accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is a chemical medication intended for use when oral administration is not feasible or when a rapid high serum concentration of erythromycin is required for treating infections caused by specific sensitive microbial strains [1] - It is also indicated for the prevention of initial rheumatic fever, recurrence of rheumatic fever, and bacterial endocarditis [1] Group 2: Financial and Market Data - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] - According to IQVIA CHPA data, the sales revenue for injectable erythromycin lactobionate in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 170 million in 2024 [1]